Clinical Trials Logo

Impulse Control Disorder clinical trials

View clinical trials related to Impulse Control Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT06237868 Recruiting - Parkinson Disease Clinical Trials

rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease

Start date: May 2024
Phase: N/A
Study type: Interventional

This study's objective is to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC) of patients with Parkinson's Disease (PD) who experience impulse control disorders (ICDs) on impulse control symptoms and cognitive behaviors linked to ICDs: reinforcement learning and delay-discounting. This is a randomized sham-controlled cross-over trial. All patients will undergo a session of active rTMS and a session of sham rTMS, with the order of sessions randomized across participants. Following recruitment and eligibility screening, the eligible participants will undergo two sessions of rTMS (active and sham), immediately followed by neurocognitive tasks and questionnaires, no more than 1-2 weeks apart. Each session will have a duration of approximately 1-1.5 hours.

NCT ID: NCT05712057 Recruiting - Anxiety Disorders Clinical Trials

Neurostimulation Versus Therapy for Problems With Emotions

Start date: May 15, 2023
Phase: N/A
Study type: Interventional

The primary goal of this clinical trial is to evaluate the unique neural and behavioral effects of a one-session training combining emotion regulation skills training, with excitatory repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC). The secondary aim is to identify key changes in the emotion regulation neural network following the combined intervention versus each of the components alone. The third aim is to explore personalized biomarkers for response to emotion regulation training. Participants will undergo brain imaging while engaging in an emotional regulation task. Participants will be randomly assigned to learn one of two emotion regulation skills. Participants will be reminded of recent stressors and will undergo different types of neurostimulation, targeted using fMRI (functional MRI) results. Participants who may practice their emotion regulation skills during neurostimulation in a one-time session. Following this training, participants will undergo another fMRI and an exit interview to assess for immediate neural and behavioral changes. Measures of emotion regulation will be assessed at a one week and a one month follow up visit.

NCT ID: NCT03146130 Recruiting - Parkinson Clinical Trials

Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders

NoISE-PD
Start date: July 5, 2018
Phase: Phase 3
Study type: Interventional

Impulse control disorders encountered in Parkinson's disease (PD) are induced by dopaminergic medications and their frequency is estimated to be nearly 20%, mainly under dopaminergic agonists (AD).

NCT ID: NCT02927002 Active, not recruiting - Clinical trials for Impulse Control Disorder

Effects of Non-invasive Brain Stimulation in Impulse Control Disorders

Start date: October 2015
Phase: N/A
Study type: Interventional

The goal of this project is to study the effect of noninvasive brain stimulation on decision-making and on brain activity in impulse control disorders.

NCT ID: NCT01683253 Completed - Clinical trials for Impulse Control Disorder

Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa

REIN-PD
Start date: November 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to see whether the ICDs(Impulse Control Disorder) are improved and neuropsychiatric traits related to ICD are changed or not when switching dopamine agonist to levodopa/carbidopa in patients with Parkinson's disease who have been treated with dopaminergic medications.

NCT ID: NCT01052831 Completed - Parkinson Disease Clinical Trials

Naltrexone for Impulse Control Disorders in Parkinson's Disease

Start date: November 2009
Phase: Phase 4
Study type: Interventional

This study will evaluate the effectiveness of naltrexone in reducing ICD symptoms in Parkinson's disease patients taking a dopamine agonist.